Research map: Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support

Back to the article

Papers in this map

  1. International consensus guidance for management of myasthenia gravis · Donald B. Sanders · 2016 · 1211 citations · Cited by this paper
  2. Burden of illness of Duchenne muscular dystrophy in Belgium: A retrospective, descriptive, cross-sectional study · 2026 · Related
  3. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial · James F. Howard · 2021 · 726 citations · Cited by this paper
  4. Minute-by minute gait variations during the 6-Minute walk test in subjects with myotonic dystrophy type 1 · 2026 · Related
  5. Late-Onset Myasthenia Gravis · Johan A. Aarli · 1999 · 136 citations · Cited by this paper
  6. Congenital myasthenic syndrome due to novel GFPT1 variant presenting with head drop and visual impairment: A case report · 2026 · Related
  7. Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China · Sushan Luo · 2024 · 48 citations · Cited by this paper
  8. Not only cross-sectional area: Echogenicity matters in nerve ultrasound studies of patients with motor multifocal neuropathy · 2026 · Related
  9. Harms of outcome switching in reports of randomised trials: CONSORT perspective · Douglas G. Altman · 2017 · 42 citations · Cited by this paper
  10. Orofacial dysfunction in persons with congenital or childhood-onset neuromuscular disorders · 2026 · Related
  11. Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod · Keiko Watanabe · 2024 · 35 citations · Cited by this paper
  12. Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis · 2026 · Related
  13. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series · Jie Song · 2024 · 33 citations · Cited by this paper
  14. Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report · 2026 · Related
  15. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis · Vera Bril · 2022 · 31 citations · Cited by this paper
  16. Expanding repeats, expanding impact: Somatic instability in myotonic dystrophy type 1 · 2026 · Related
  17. Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series · Hong Ye · 2024 · 27 citations · Cited by this paper
  18. Effects of intermittent corticosteroids on scoliosis, bone density, and vertebral fractures in duchenne muscular dystrophy · 2026 · Related
  19. Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis · Jing Ma · 2024 · 24 citations · Cited by this paper
  20. A qualitative study of the discrepancy between patient expectations and assessment practices in 5q-adult spinal muscular atrophy in France · 2026 · Related
  21. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report · Zhouao Zhang · 2024 · 15 citations · Cited by this paper
  22. Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report · Hiroya Ohara · 2024 · 15 citations · Cited by this paper
  23. Myasthenia gravis: The evolving therapeutic landscape · Gil I. Wolfe · 2024 · 12 citations · Cited by this paper
  24. What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis? · Fiammetta Vanoli · 2022 · 10 citations · Cited by this paper
  25. Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis · Shahar Shelly · 2025 · 8 citations · Cited by this paper
  26. First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report · Isabelle Kwiedor · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)